These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28186287)

  • 1. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
    Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
    Kim M; Chung YS; Kim KA; Shim HS
    Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size.
    Takahashi Y; Ishii G; Aokage K; Hishida T; Yoshida J; Nagai K
    Lung Cancer; 2013 Feb; 79(2):118-24. PubMed ID: 23177278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor.
    Araki K; Kidokoro Y; Hosoya K; Wakahara M; Matsuoka Y; Takagi Y; Haruki T; Miwa K; Taniguchi Y; Horie S; Nakamura H
    Anticancer Res; 2014 Jun; 34(6):3153-6. PubMed ID: 24922687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society.
    Xu L; Tavora F; Battafarano R; Burke A
    Am J Surg Pathol; 2012 Feb; 36(2):273-82. PubMed ID: 22198010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database.
    Bertoglio P; Querzoli G; Ventura L; Aprile V; Cattoni MA; Nachira D; Lococo F; Rodriguez Perez M; Guerrera F; Minervini F; Gnetti L; Bacchin D; Franzi F; Rindi G; Bellafiore S; Femia F; Viti A; Bogina GS; Kestenholz P; Ruffini E; Paci M; Margaritora S; Imperatori AS; Lucchi M; Ampollini L; Terzi AC
    J Surg Oncol; 2021 Feb; 123(2):560-569. PubMed ID: 33169397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma.
    Hou Y; Song W; Chen M; Zhang J; Luo Q; Um SW; Facchinetti F; Bongiolatti S; Zhou Q
    Transl Lung Cancer Res; 2022 Jan; 11(1):64-74. PubMed ID: 35242628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
    Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma.
    Sasada S; Nakayama H; Miyata Y; Tsubokawa N; Mimae T; Yoshiya T; Murakami S; Ito H; Okada M
    Ann Thorac Surg; 2015 Mar; 99(3):956-60. PubMed ID: 25620597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
    Song W; Hou Y; Zhang J; Zhou Q
    Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.
    Song Z; Zhu H; Guo Z; Wu W; Sun W; Zhang Y
    Eur J Surg Oncol; 2013 Nov; 39(11):1262-8. PubMed ID: 24063970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
    J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.
    Yoshiya T; Mimae T; Tsutani Y; Tsubokawa N; Sasada S; Miyata Y; Kushitani K; Takeshima Y; Murakami S; Ito H; Nakayama H; Okada M
    Ann Thorac Surg; 2016 Nov; 102(5):1668-1673. PubMed ID: 27344277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
    Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung.
    Lin G; Li H; Kuang J; Tang K; Guo Y; Han A; Xie C
    Am J Clin Pathol; 2018 Mar; 149(5):373-378. PubMed ID: 29538611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.
    Kadota K; Villena-Vargas J; Yoshizawa A; Motoi N; Sima CS; Riely GJ; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Apr; 38(4):448-60. PubMed ID: 24472852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristic immunophenotype of solid subtype component in lung adenocarcinoma.
    Takuwa T; Ishii G; Nagai K; Yoshida J; Nishimura M; Hishida T; Neri S; Hasegawa S; Ochiai A
    Ann Surg Oncol; 2012 Nov; 19(12):3943-52. PubMed ID: 22669454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
    Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
    Yoshizawa A; Motoi N; Riely GJ; Sima CS; Gerald WL; Kris MG; Park BJ; Rusch VW; Travis WD
    Mod Pathol; 2011 May; 24(5):653-64. PubMed ID: 21252858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.